Exhibit 99.1
Liquidia Reports Fourth Quarter and Full-Year 2019
Financial Results and Provides Corporate Update
Submitted New Drug Application (NDA) for LIQ861 in January 2020
Management to Host Webcast and Conference Call Today at 8:00 a.m. ET
RESEARCH TRIANGLE PARK, NC, March 11, 2020 – Liquidia Technologies, Inc. (Nasdaq: LQDA) (“Liquidia” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products utilizing its proprietary PRINT® technology, today reported financial results for the fourth quarter and full-year ended December 31, 2019, and provided a corporate update.
“We are pleased to have submitted our NDA for LIQ861, an important milestone in our continued evolution towards becoming a fully-integrated, commercial biopharmaceutical company. We were also pleased to raise additional equity capital through a private placement and ATM sales during the fourth quarter. We look forward to continuing to advance our pipeline based upon our PRINT technology to bring meaningful benefits to patients,” stated Neal Fowler, Liquidia’s Chief Executive Officer.
Corporate Update
| · | Completed INSPIRE clinical trial and submitted NDA for LIQ861 |
Based upon the favorable results of the pivotal Phase 3 INSPIRE trial and pharmacokinetic studies in healthy volunteers, the Company submitted an NDA for LIQ861 to the U.S. Food and Drug Administration (FDA) on January 24, 2020 under the 505(b)(2) regulatory pathway. As previously reported, the safety and tolerability profile of LIQ861, the primary endpoint of the INSPIRE trial, was observed to be favorable. Also, as previously reported, a high rate of sustained treatment benefit across certain exploratory endpoints was observed, including the maintenance or improvement of New York Heart Association (NYHA) functional class in more than 90% of all patients enrolled in the trial who completed two months of treatment. As recently reported at the 14th Annual Pulmonary Vascular Research Institute (PVRI) Conference, results of a pharmacokinetic study in healthy volunteers have also demonstrated that treprostinil exposure from a 79.5 mcg dose of LIQ861 is comparable to that of nine breaths of Tyvaso, the reference listed drug.
| · | Continuing clinical studies to evaluate long-term safety, tolerability and hemodynamic effects of LIQ861 |
Most patients from INSPIRE continue to receive LIQ861 in the extension study, including several patients with at least 18 months of treatment. The safety and tolerability profile of LIQ861 in this extension study remains consistent with the results seen in the INSPIRE trial. In addition, a clinical study has been initiated in patients with pulmonary arterial hypertension at certain investigational sites in Europe to characterize the hemodynamic dose-response relationship to LIQ861.
1
| · | Advancing the Company's pipeline to leverage the demonstrated advantages of PRINT technology |
The Company continues to conduct Phase 2-enabling toxicology studies for LIQ865, a proprietary formulation of bupivacaine, a non-opioid anesthetic, targeting local post-operative pain relief for three to five days following a single administration. Results of the ongoing toxicology work are expected during the second half of 2020, and, subject to the availability of capital, the Company intends to determine next steps with regard to the clinical development program for LIQ865 following a review of all toxicology results. Additionally, the Company has recently initiated a pre-clinical program to develop an inhaled product leveraging the benefits of PRINT technology to engineer particles with precise, uniform, aerodynamic size and shape for deep lung delivery.
| · | Completion of private placement and ATM sales |
In December 2019, the Company completed a private placement of common stock, resulting in gross proceeds of $22.4 million. Additionally, the Company raised gross proceeds of $8.4 million through the sale of common stock pursuant to the Company's “at-the-market” (ATM) equity issuance facility during the fourth quarter.
Fourth Quarter 2019 Financial Results
Revenues for the three months ended December 31, 2019 were $0, compared to $0.6 million for the three months ended December 31, 2018. The decrease in revenues was due to the full recognition during the second quarter of 2019 of $8.1 million of deferred revenue from the Company's collaboration with GlaxoSmithKline plc (GSK) following the Company's determination that the earnings process related to the collaboration had been completed.
Research and development expenses for the fourth quarter of 2019 increased to $8.2 million from $8.0 million for the fourth quarter of 2018, primarily due to an increase in non-clinical expenses related to the LIQ865 program.
General and administrative expenses for the fourth quarter of 2019 increased to $5.8 million from $2.3 million for the fourth quarter of 2018, primarily due to increased commercial spending related to the LIQ861 program.
2
Loss from operations for the fourth quarter of 2019 increased to $14.0 million from $9.8 million for the fourth quarter of 2018, primarily due to an increase in commercial expenses related to the LIQ861 program as well as an increase in non-clinical expenses related to the LIQ865 program.
Interest income was $0.1 million for the fourth quarter of 2019, compared with $0.2 million for the fourth quarter of 2018, reflecting a lower average cash balance during the fourth quarter of 2019.
Interest expense was $0.6 million for the fourth quarter of 2019, compared with $0.2 million for the fourth quarter of 2018, reflecting a higher level of debt outstanding during the fourth quarter of 2019.
Net loss for the fourth quarter of 2019 increased to $14.5 million from $9.7 million for the fourth quarter of 2018, primarily due to an increase in commercial expenses related to the LIQ861 program as well as an increase in non-clinical expenses related to the LIQ865 program.
Cash and cash equivalents totaled $55.8 million at December 31, 2019 and reflect the completion of the Company's private placement and ATM sales that resulted in gross proceeds of $22.4 million and $8.4 million (net proceeds of $21.1 million and $8.2 million), respectively, during the fourth quarter of 2019. There were 28.2 million shares outstanding as of December 31, 2019.
Full Year 2019 Financial Results
Revenues for the year ended December 31, 2019 were $8.1 million, compared to $2.7 million for the year ended December 31, 2018. The increase in revenues was due to the full recognition in the second quarter of 2019 of $8.1 million of deferred revenue from the Company's collaboration with GSK following the Company's determination that the earnings process related to the collaboration had been completed.
Cost of sales for 2019 increased to $0.8 million from $0.1 million for 2018 due to the amortization of the deferred sublicense payments that were previously paid to the University of North Carolina at Chapel Hill related to the Company’s collaboration with GSK following the Company’s determination that the earnings process related to the collaboration has been completed.
Research and development (R&D) expenses for 2019 increased to $40.5 million from $28.7 million for 2018, primarily due to an increase in expenses related to the LIQ861 clinical program as well an increase in non-clinical expenses related to the LIQ865 program.
General and administrative expenses for 2019 increased to $13.6 million from $8.8 million for 2018, primarily due to increased commercial spending related to the LIQ861 program.
3
Loss from operations for 2019 increased to $46.8 million from $34.9 million for 2018, primarily due to an increase in expenses related to the LIQ861 program, including both R&D and commercial expenses, and an increase in non-clinical expenses related to the LIQ865 program, partially offset by the increase in revenues noted above.
Interest income was $0.6 million for 2019, compared with $0.3 million for 2018, reflecting a higher average cash balance in 2019.
Interest expense was $1.4 million for 2019, compared with $19.0 million for 2018, reflecting a lower level of debt during the year 2019 and the conversion of $27.4 million of convertible notes into shares of Series D preferred stock in February 2018.
Net loss for 2019 decreased to $47.6 million from $53.1 million for 2018, primarily due to a decrease in interest expense and an increase in revenues, which were partially offset by an increase in expenses related to the LIQ861 program, including both R&D and commercial expenses, as well as an increase in non-clinical expenses related to the LIQ865 program.
Webcast and Conference Call
Liquidia’s management team will host a webcast and conference call at 8:00 a.m. ET today to discuss the financial results and provide a corporate update. The live call may be accessed by dialing 1-877-707-8711 (domestic) and 1-857-270-6219 (international) and entering the conference code: 6994366. A live and archived webcast of the call will be available on the Events & Presentations page of Liquidia’s website.
About Liquidia
Liquidia is a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products utilizing itsproprietaryPRINT® technology to transform the lives of patients. Currently, Liquidia is focused on the development of two product candidates using its PRINT particle engineering platform:LIQ861 for the treatment of pulmonary arterial hypertension andLIQ865 for the treatment of local post-operative pain. LIQ861 is designed to improve the therapeutic profile of treprostinil with the goal of enhancing deep-lung delivery and achieving higher dose levels than current inhaled therapies by using a convenient, palm-sized dry powder inhaler. In January 2020, Liquidia submitted a New Drug Application (NDA) for LIQ861 to the U.S. Food and Drug Administration (FDA). LIQ865, for which Liquidia has completed two phase 1 clinical trials, is designed to deliver sustained-release particles of bupivacaine, a non-opioid anesthetic, to treat local post-operative pain for three to five days through a single administration. For more information visit Liquidia’s website atwww.liquidia.com.
* Tyvaso® is a registered trademark of United Therapeutics Corporation.
4
Forward Looking Statements
This press release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical facts, including statements regarding our future results of operations and financial position, our strategic and financial initiatives, our business strategy and plans and our objectives for future operations, are forward-looking statements. Such forward-looking statements, including statements regarding clinical trials, clinical studies and other clinical work (including the funding therefor, anticipated patient enrollment, safety data, study data, trial outcomes, timing or associated costs), regulatory applications and related timelines, including U.S. Food and Drug Administration (FDA) acceptance of the New Drug Application (NDA) submission for LIQ861 and potential approval thereof, and our ability to execute on our strategic or financial initiatives, involve significant risks and uncertainties and actual results could differ materially from those expressed or implied herein. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would,” and similar expressions are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives and financial needs. These forward-looking statements are subject to a number of risks discussed in our filings with the Securities and Exchange Commission, as well as a number of uncertainties and assumptions. Moreover, we operate in a very competitive and rapidly changing environment and our industry has inherent risks. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the future events discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Nothing in this press release should be regarded as a representation by any person that these goals will be achieved, and we undertake no duty to update our goals or to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise.
| Contact Information |
| Investors: |
| Jason Adair |
| Vice President, Corporate Development and Strategy |
| 919.328.4400 |
| jason.adair@liquidia.com |
-Financial Tables Follow-
5
Liquidia Technologies, Inc.
Balance Sheets
| December 31, 2019 | December 31, 2018 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash | $ | 55,796,378 | $ | 39,534,985 | ||||
| Accounts receivable, net | — | 272,557 | ||||||
| Prepaid expenses and other current assets | 590,251 | 219,057 | ||||||
| Total current assets | 56,386,629 | 40,026,599 | ||||||
| Property, plant and equipment, net | 9,253,965 | 8,130,708 | ||||||
| Operating lease right-of-use assets, net | 2,823,430 | — | ||||||
| Prepaid expenses and other assets | 378,043 | 1,260,951 | ||||||
| Total assets | $ | 68,842,067 | $ | 49,418,258 | ||||
| Liabilities and stockholders’ equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 3,498,043 | $ | 3,235,949 | ||||
| Accrued compensation | 3,164,687 | 2,515,519 | ||||||
| Accrued stock offering expenses | 1,289,413 | — | ||||||
| Other accrued expenses | 1,525,919 | 1,459,182 | ||||||
| Deferred rent | — | 268,599 | ||||||
| Current portion of operating lease liabilities | 566,390 | — | ||||||
| Current portion of finance lease liabilities | 1,244,229 | 452,703 | ||||||
| Current portion of long-term debt | 5,585,637 | 316,906 | ||||||
| Total current liabilities | 16,874,318 | 8,248,858 | ||||||
| Long-term operating lease liabilities | 5,670,971 | — | ||||||
| Long-term finance lease liabilities | 1,056,747 | 376,082 | ||||||
| Long-term deferred rent | — | 2,406,084 | ||||||
| Long-term deferred revenue | — | 8,071,920 | ||||||
| Long-term debt | 10,292,484 | 11,627,643 | ||||||
| Total liabilities | 33,894,520 | 30,730,587 | ||||||
| Commitments and contingencies | ||||||||
| Stockholders’ equity: | ||||||||
| Common stock — $0.001 par value, 40,000,000 shares authorized as of December 31, 2019 and December 31, 2018, 28,231,267 and 15,519,469 issued and outstanding as of December 31, 2019 and December 31, 2018, respectively | 28,231 | 15,520 | ||||||
| Additional paid-in capital | 250,158,766 | 185,726,048 | ||||||
| Accumulated deficit | (215,239,450 | ) | (167,053,897 | ) | ||||
| Total stockholders’ equity | 34,947,547 | 18,687,671 | ||||||
| Total liabilities and stockholders’ equity | $ | 68,842,067 | $ | 49,418,258 | ||||
6
Liquidia Technologies, Inc.
Statements of Operations and Comprehensive Loss
| Three Months Ended | Year Ended | |||||||||||||||
| December 31, | December 31, | |||||||||||||||
| 2019 | 2018 | 2019 | 2018 | |||||||||||||
| Revenues | $ | — | $ | 568,402 | $ | 8,072,120 | $ | 2,706,981 | ||||||||
| Costs and expenses: | ||||||||||||||||
| Cost of sales | — | — | 807,192 | 121,391 | ||||||||||||
| Research and development | 8,160,904 | 7,998,554 | 40,491,358 | 28,699,576 | ||||||||||||
| General and administrative | 5,789,199 | 2,329,196 | 13,597,119 | 8,754,088 | ||||||||||||
| Total costs and expenses | 13,950,103 | 10,327,750 | 54,895,669 | 37,575,055 | ||||||||||||
| Loss from operations | (13,950,103 | ) | (9,759,348 | ) | (46,823,549 | ) | (34,868,074 | ) | ||||||||
| Other income (expense): | ||||||||||||||||
| Interest income | 93,855 | 165,016 | 613,716 | 304,981 | ||||||||||||
| Interest expense | (636,193 | ) | (229,098 | ) | (1,373,622 | ) | (18,988,176 | ) | ||||||||
| Gain on early extinguishment of long-term debt | — | 137,695 | — | 137,695 | ||||||||||||
| Derivative and warrant fair value adjustments | — | — | — | 277,715 | ||||||||||||
| Total other income (expense), net | (542,338 | ) | 73,613 | (759,906 | ) | (18,267,785 | ) | |||||||||
| Net income (loss) | (14,492,441 | ) | (9,685,735 | ) | (47,583,455 | ) | (53,135,859 | ) | ||||||||
| Other comprehensive income (loss) | $ | — | $ | — | $ | — | $ | — | ||||||||
| Comprehensive income (loss) | (14,492,441 | ) | (9,685,735 | ) | (47,583,455 | ) | (53,135,859 | ) | ||||||||
| Net income (loss) per common share: | ||||||||||||||||
| Basic | $ | (0.71 | ) | $ | (0.62 | ) | $ | (2.57 | ) | $ | (7.42 | ) | ||||
| Diluted | (0.72 | ) | (0.62 | ) | (2.59 | ) | (7.51 | ) | ||||||||
| Weighted average common shares outstanding: | ||||||||||||||||
| Basic | 20,357,315 | 15,692,205 | 18,482,455 | 7,163,304 | ||||||||||||
| Diluted | 20,251,041 | 15,498,802 | 18,371,083 | 7,078,757 | ||||||||||||
7